UPDATE: Lexicon Announces FDA Approval of INPEFA™ (sotagliflozin) for Treatment of Heart FailureGlobeNewsWire • 06/15/23
Lexicon Pharmaceuticals to Participate in the Jefferies 2023 Global Healthcare ConferenceGlobeNewsWire • 06/06/23
Lexicon Announces Closing of Public Offering and Concurrent Private Placement, Including Full Exercise of Options to Purchase Additional SharesGlobeNewsWire • 06/05/23
Lexicon Announces FDA Approval of INPEFA™ (sotagliflozin) for Treatment of Heart FailureGlobeNewsWire • 05/26/23
Wall Street's Counting on an FDA Nod for This Growth Stock to Nearly Double, but Should You?The Motley Fool • 05/11/23
New Analysis Finds Sotagliflozin to Be a Cost-Effective Treatment at Commonly Accepted Willingness-to-Pay Threshold in Patients with Worsening Heart FailureGlobeNewsWire • 05/10/23
Lexicon Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 05/02/23
Lexicon Pharmaceuticals to Host First Quarter 2023 Financial Results Conference Call and Webcast on May 2, 2023GlobeNewsWire • 04/28/23
Lexicon To Present Results From LX9211 Phase 2 Trial In Postherpetic Neuralgia At The 2023 American Academy Of Neurology (AAN) Annual Meeting And The British Pain Society (BPS) 56th Annual Scientific Meeting 2023GlobeNewsWire • 04/21/23
Lexicon Pharmaceuticals to Participate in The 22nd Annual Needham Virtual Healthcare ConferenceGlobeNewsWire • 04/17/23
New Analyses of Sotagliflozin Showing Time to Clinical Benefit Presented at The American College of Cardiology's 72nd Annual Scientific Session Together With World Heart Federation's World Congress of CardiologyGlobeNewsWire • 03/04/23
Lexicon Reveals “INTO THE DARK” Awareness Campaign About Vulnerable and Dangerous Period of Time Faced by Heart Failure Patients Following HospitalizationGlobeNewsWire • 03/04/23
Lexicon Pharmaceuticals Reports Fourth Quarter 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 03/02/23
Lexicon Pharmaceuticals to Host Fourth Quarter 2022 Financial Results Conference Call and Webcast on March 2, 2023GlobeNewsWire • 02/28/23